Specify Company / Ticker to Get the Summary
Citius Pharmaceuticals Inc
CTXRCitius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. The Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido completed. The company was founded in 2007 and is headquartered in Cranford, New Jersey. Address: 11 Commerce Drive, Cranford, NJ, United States, 07016
Analytics
WallStreet Target Price
4.67 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures CTXR
Dividend Analytics CTXR
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History CTXR
Stock Valuation CTXR
Financials CTXR
Results | 2019 | Dynamics |